Tosk, Inc

BioAssay Systems, established in 2003, specializes in developing and marketing innovative high-throughput assay solutions tailored to the life sciences industry. With over 250 assay kits and a commitment to quality, the company leverages more than 50 years of combined experience in modern drug discovery to meet the evolving demands of researchers worldwide. Offering an expansive catalog of over 280 products, BioAssay Systems ensures that its assays are user-friendly and extensively validated, allowing for minimal optimization time. The company prides itself on competitive pricing, expert technical support from the scientists who develop the assays, and a global presence with distributors in over 60 countries. Generated from the website

Exelixis is an integrated drug discovery and development company. The company utilizes cutting-edge genomic, molecular biology and combinatorial chemistry technologies to develop innovative therapies for significant human diseases. Its primary mission is to improve patient care by developing proprietary human therapeutics that target the complex molecular causes of disease. Exelixis has built a research and discovery platform. The Exelixis clinical development pipeline includes compounds in cancer and renal disease. The company s pre-clinical pipeline is comprised of six programs. The pre-clinical oncology programs consist of development candidates that focus on inhibiting kinases. In its pre-clinical metabolic disease programs, Exelixis has developed small molecules that modulate nuclear hormone receptors that implicate various metabolic and cardiovascular disorders. Corporate headquarters are in San Francisco. The research facility is in Portland, Ore.

Portola Pharmaceuticals is a Bay Area–based pharmaceuticals company with a focus on bioresearch and drug development. Their efforts are directed towards global markets, specifically in the treatment of cardiovascular disease and inflammation. Generated from their available business information